Back

A novel strategy for reducing time between antiplatelet drug cessation and urgent CABG surgery following acute coronary syndromes

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Risk modification in coronary artery bypass surgery Coronary Arteries ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Robert Storey

University of Sheffield, Sheffield (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Hybrid coronary revascularization vs. coronary artery bypass grafting in multivessel coronary artery disease
Doctor S. Corradetti (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Long term outcomes of coronary artery bypass grafting using the pure internal thoracic artery (PITA-CABG) technique
Mr H. Yong (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Chronic coronary total occlusions: does surgery hold the answer?
Doctor A. Silva (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Influence of baseline Hb1Ac and antiplatelet therapy on 5-year clinical outcomes after coronary artery bypass grafting.
Doctor Q. Liu (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
A head-to-head comparison of physiology versus angiography-guided coronary artery bypass grafting
Doctor A. Silva (Coimbra, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Risk modification in coronary artery bypass surgery

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
The impact of ticagrelor therapy on CABG-related bleeding in patients with STEMI managed with pPCI
thumbnail
Congress Presentation
Intraoperative antithrombotic drug removal during heart transplantation: insights from the international safe and timely antithrombotic removal (STAR) registry
thumbnail
Congress Presentation
Effect of evolocumab on platelet function in patients with acute coronary syndromes. An analysis of the randomized, double-blind, placebo-controlled EVOPACS Trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources